Secretogranin III as a novel target for the therapy of choroidal neovascularization

Michelle E. LeBlanc, Weiwen Wang, Yanli Ji, Hong Tian, Dachuan Liu, Xuxiang Zhang, Wei Li

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Wet age-related macular degeneration (AMD) with choroidal neovascularization (CNV) is a leading cause of vision loss in the elderly. The advent of anti-vascular endothelial growth factor (VEGF) drugs represents a major breakthrough in wet AMD therapy but with limited efficacy to improve visual acuity. Secretogranin III (Scg3, SgIII) was recently discovered as a novel angiogenic factor with VEGF-independent mechanisms. Scg3-neutralizing monoclonal antibody (mAb) was reported to alleviate pathological retinal neovascularization in oxygen-induced retinopathy mice and retinal vascular leakage in diabetic mice with high efficacy and disease selectivity. Herein we investigated whether Scg3 is a novel angiogenic target for CNV therapy in mouse models. We found that anti-Scg3 ML49.3 mAb inhibited Scg3-induced proliferation and Src phosphorylation in human retinal microvascular endothelial cells. Intravitreal injection of Scg3-neutralizing polyclonal antibodies (pAb) or mAb significantly attenuated laser-induced CNV leakage, CNV 3D volume, lesion area and vessel density. Furthermore, subcutaneous administration of Scg3-neutralizing pAb or mAb significantly prevented Matrigel-induced CNV. The efficacy of anti-Scg3 pAb or mAb was comparable to VEGF inhibitor aflibercept. These findings suggest that Scg3 plays an important role in CNV pathogenesis and that anti-Scg3 mAb efficiently ameliorates laser- or Matrigel-induced CNV.

Original languageEnglish (US)
Pages (from-to)120-126
Number of pages7
JournalExperimental Eye Research
StatePublished - Apr 2019


  • AMD
  • Angiogenic factor
  • Anti-angiogenic therapy
  • CNV
  • Choroidal neovascularization
  • Scg3
  • Secretogranin III

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Secretogranin III as a novel target for the therapy of choroidal neovascularization'. Together they form a unique fingerprint.

Cite this